Share-based Payment Arrangement, Expense of Enliven Therapeutics, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enliven Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Enliven Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $7,185,000, a 39% increase year-over-year.
  • Enliven Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $27,047,000, a 51% increase year-over-year.
  • Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20,174,000, a 56% increase from 2023.
  • Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $12,914,000, a 305% increase from 2022.
  • Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,191,000, a 66% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Enliven Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $27,047,000 $7,185,000 +$2,009,000 +39% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $25,038,000 $7,724,000 +$2,580,000 +50% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $22,458,000 $6,799,000 +$2,284,000 +51% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $20,174,000 $5,339,000 +$2,283,000 +75% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $17,891,000 $5,176,000 +$1,775,000 +52% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $16,116,000 $5,144,000 +$949,000 +23% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $15,167,000 $4,515,000 +$2,253,000 +100% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $12,914,000 $3,056,000 +$2,321,000 +316% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $10,593,000 $3,401,000 +$2,300,000 +209% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $8,293,000 $4,195,000 +$3,494,000 +498% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $4,799,000 $2,262,000 +$1,608,000 +246% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $3,191,000 $735,000 +$1,678,000 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $1,513,000 $1,101,000 +$98,000 +9.8% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $1,415,000 $701,000 -$216,000 -24% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,631,000 $654,000 -$293,000 -31% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $1,924,000 $943,000 -$1,622,000 -239% 01 Oct 2021 31 Dec 2021 8-K 23 Jun 2023
Q3 2021 $3,546,000 $1,003,000 +$361,000 +56% 01 Jul 2021 30 Sep 2021 10-Q 25 Oct 2022 2022 Q3
Q2 2021 $3,185,000 $917,000 +$367,000 +67% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $2,818,000 $947,000 +$587,000 +163% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $2,231,000 $679,000 +$382,000 +129% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $1,849,000 $642,000 +$332,000 +107% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $1,517,000 $550,000 +$353,000 +179% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $1,164,000 $360,000 +$265,000 +279% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $899,000 $297,000 01 Oct 2019 31 Dec 2019 10-K 05 Mar 2021 2020 FY
Q3 2019 $310,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $197,000 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $95,000 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1

Enliven Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $20,174,000 +$7,260,000 +56% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $12,914,000 +$9,723,000 +305% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $3,191,000 +$1,267,000 +66% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $1,924,000 -$307,000 -14% 01 Jan 2021 31 Dec 2021 8-K 23 Jun 2023
2020 $2,231,000 +$1,332,000 +148% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $899,000 01 Jan 2019 31 Dec 2019 10-K 05 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.